Etrasimod
Velsipity (etrasimod) is a small molecule pharmaceutical. Etrasimod was first approved as Velsipity on 2023-10-12. It is used to treat ulcerative colitis in the USA. The pharmaceutical is active against sphingosine 1-phosphate receptor 1. In addition, it is known to target sphingosine 1-phosphate receptor 4 and sphingosine 1-phosphate receptor 5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| velsipity | New Drug Application | 2024-09-24 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ETRASIMOD ARGININE, VELSIPITY, PFIZER | |||
| 2028-10-12 | NCE | ||
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
25 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 5 | 5 | — | 4 | 14 |
| Colitis | D003092 | EFO_0003872 | K52.9 | — | 6 | 5 | — | 3 | 14 |
| Ulcer | D014456 | MPATH_579 | — | — | 5 | 5 | — | 2 | 12 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 2 | 1 | — | — | 2 |
| Eczema | D004485 | HP_0000964 | L30.9 | — | 2 | 1 | — | — | 2 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | 2 | 1 | — | — | 2 |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | — | 1 | — | 1 | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | 1 | — | — | 1 | 2 |
| Eosinophilic esophagitis | D057765 | EFO_0004232 | K20.0 | — | 1 | — | — | — | 1 |
| Esophagitis | D004941 | HP_0100633 | K20 | — | 1 | — | — | — | 1 |
| Alopecia areata | D000506 | EFO_0004192 | L63 | — | 1 | — | — | — | 1 |
| Alopecia | D000505 | HP_0002293 | L64 | — | 1 | — | — | — | 1 |
| Biliary liver cirrhosis | D008105 | — | K74.3 | — | 1 | — | — | — | 1 |
| Cholangitis | D002761 | HP_0030151 | K83.0 | — | 1 | — | — | — | 1 |
| Intestinal diseases | D007410 | HP_0002242 | K63.9 | — | 1 | — | — | — | 1 |
| Pyoderma gangrenosum | D017511 | EFO_0006835 | L88 | — | 1 | — | — | — | 1 |
| Pyoderma | D011711 | HP_0000999 | L08.0 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Etrasimod |
| INN | etrasimod |
| Description | Etrasimod is an organic heterotricyclic compound that is 1,2,3,4-tetrahydrocyclopenta[b]indole substituted by carboxymethyl and [4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy groups at positions 3R and 7, respectively. It is a potent and functional antagonist of the sphingosine-1-phosphate-1 (S1P1) receptor (IC50 = 1.88 nM in CHO cells). It has a role as an antibacterial agent, a sphingosine-1-phosphate receptor 1 antagonist, an immunosuppressive agent and an anti-inflammatory drug. It is a member of (trifluoromethyl)benzenes, a member of cyclopentanes, an aromatic ether, a monocarboxylic acid and an organic heterotricyclic compound. It is a conjugate acid of an etrasimod(1-). |
| Classification | Small molecule |
| Drug class | immunomodulators |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21 |
Identifiers
| PDB | — |
| CAS-ID | 1206123-37-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3358920 |
| ChEBI ID | — |
| PubChem CID | 44623998 |
| DrugBank | DB14766 |
| UNII ID | 6WH8495MMH (ChemIDplus, GSRS) |
Target
Agency Approved
S1PR1
S1PR1
Organism
Homo sapiens
Gene name
S1PR1
Gene synonyms
CHEDG1, EDG1
NCBI Gene ID
Protein name
sphingosine 1-phosphate receptor 1
Protein synonyms
CD363, Endothelial differentiation G-protein coupled receptor 1, endothelial differentiation, sphingolipid G-protein-coupled receptor, 1, S1P receptor 1, S1P receptor Edg-1, Sphingosine 1-phosphate receptor Edg-1, sphingosine 1-phosphate receptor EDG1
Uniprot ID
Mouse ortholog
S1pr1 (13609)
sphingosine 1-phosphate receptor 1 (Q9R235)
Alternate
S1PR4
S1PR4
S1PR5
S1PR5
Organism
Homo sapiens
Gene name
S1PR4
Gene synonyms
EDG6
NCBI Gene ID
Protein name
sphingosine 1-phosphate receptor 4
Protein synonyms
Endothelial differentiation G-protein coupled receptor 6, endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 6, S1P receptor 4, S1P receptor Edg-6, Sphingosine 1-phosphate receptor Edg-6
Uniprot ID
Mouse ortholog
S1pr4 (13611)
sphingosine 1-phosphate receptor 4 (Q9Z0L1)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 289 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
102 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use